Can FDA Approval Bolster DexCom?

Published by
ValueWalk

DexCom, Inc recently received FDA approval for their new G7 continuous glucose monitorThe improved device–and the relationships it is helping them build-show great promise for the future.DexCom stock has been struggling, but this news may be a catalyst.DexCom, Inc. (NASDAQ:DXCM) is a continuous glucose monitoring (CGM) company. In early December, they received approval from the United States Food and Drug Administration (FDA) for their new monitor, the G7. This device assists patients with Type 1 and Type 2 diabetes and gestational diabetes. Furthermore, the seemingly simple, all-in-one wearab…

Read More

See also  UFC 245 results: Kamaru Usman finishes bloody Colby Covington late in fifth round

Leave a Reply